APA (7th ed.) Citation

Vicier, C., Sfumato, P., Isambert, N., Dalenc, F., Robert, M., Levy, C., . . . Sabatier, R. (2021). TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, 159, 205. https://doi.org/10.1016/j.ejca.2021.09.040

Chicago Style (17th ed.) Citation

Vicier, Cecile, et al. "TAKTIC: A Prospective, Multicentre, Uncontrolled, Phase IB/II Study of LY2780301, a P70S6K/AKT Inhibitor, in Combination with Weekly Paclitaxel in HER2-negative Advanced Breast Cancer Patients." European Journal of Cancer 159 (2021): 205. https://doi.org/10.1016/j.ejca.2021.09.040.

MLA (9th ed.) Citation

Vicier, Cecile, et al. "TAKTIC: A Prospective, Multicentre, Uncontrolled, Phase IB/II Study of LY2780301, a P70S6K/AKT Inhibitor, in Combination with Weekly Paclitaxel in HER2-negative Advanced Breast Cancer Patients." European Journal of Cancer, vol. 159, 2021, p. 205, https://doi.org/10.1016/j.ejca.2021.09.040.